Table 1.
CAF Metadata | Role in CRC Progression | Clinical Relevance | |||||||
---|---|---|---|---|---|---|---|---|---|
Name of Factor | Characteristics of CAFs Expressing or Secreting This Factor | Characteristics of Tumors Which the CAFs Originated From | CRC Proliferation | CRC Invasion/Migration | Angiogenesis | Therapy Resistance | Immune Evasion | Organ Metastasis | Association High Expression Levels in CAFs & Poor Clinical Outcomes |
Exosomal circular RNA SLC7A6 [112] | - | Primary tumor; no neo-adjuvant treatment |
↑ | ↑ | - | - | - | - | Yes [112] |
HIC-5 [109] | Co-localization with α-SMA | Primary tumor | ↑ | - | - | - | - | - | - |
COX-2 [142,143] | - | Primary tumor | ↑ | - | - | - | - | - | - |
Snail-1 [110] | Co-localization with α-SMA and FAP | Primary tumor | ↑ | ↑ | - | - | - | - | Yes [144] |
FGF-1 [111] | Vimentin-positive | Primary tumor | ↑ | ↑ | ↑ | - | - | - | - |
FGF-3 [111] | Vimentin-positive | Primary tumor | ↑ | ↑ | ↑ | - | - | - | - |
Wnt2 [114,115,116] | - | Primary tumor; rectum; stage II-IV; well/moderate differentiation [114]. Not described in [115,116] |
↑ | ↑ | ↑ | - | - | - | Yes [114,115] |
miRNA-21 [118,119] | - | Primary tumor; rectum & sigmoid; stage II-III; well/moderate differentiation; microsatellite stable; no neo-adjuvant treatment | ↑ | ↑ | - | - | - | ↑ | Yes [117] |
CD10 [81] | - | Primary tumor; rectum and colon; stage II-III; well/moderate differentiation | ↑ | ↑ | - | - | - | - | - |
CLEC3B [145] | - | Primary tumor | - | ↑ | - | - | - | - | Yes [145] 1 |
Podoplanin [79] | - | - | - | ↓ | - | - | - | - | No [79,80] 2 |
SPARC [146] | - | Primary tumor | - | ↑ | - | - | - | - | Yes [146] |
IGF-2 [147] | - | Primary tumor | = | ↑ | - | - | - | ↑ | Yes [147] |
RAB31 [148] | Co-localization with α-SMA and vimentin | Primary tumor | = | ↑ | - | - | - | - | Yes [148] |
CCBE1 [149] | Co-localization with α-SMA | Primary tumor | - | - | ↑ | - | - | - | Yes [149] |
miRNA-31 [122] | - | Primary tumor; no neo-adjuvant treatment |
- | - | - | ↑ | - | - | - |
miRNA-93–5p [123] | - | Primary tumor | - | - | - | ↑ | - | - | - |
CRC-associated lncRNA [125] | FAP-positive, co-localization with α-SMA | Primary tumor | - | - | - | ↑ | - | - | - |
lncRNA H19 [124] | - | Primary tumor | - | - | - | ↑ | - | - | - |
TGF-β2 [126] | - | Primary tumor | - | - | - | ↑ | - | - | Yes [126] |
CXCL5 [136] | - | Primary tumor | - | - | - | - | ↑ | - | - |
CD70 [138] | Co-localization with α-SMA and FAP | Primary tumor | - | ↑ | - | - | ↑ | - | Yes [138,141] |
CD73 [140] | Co-localization with α-SMA | Primary tumor | - | - | - | - | ↑ | - | Yes [140] |
Endoglin [150] | Co-localization with α-SMA | Primary tumor | - | - | - | - | - | ↑ | Yes [150] |
BMP2 [151] | - | Primary tumor | - | ↑ | - | - | - | ↑ | Yes [151] 3 |
IL-11 [63] | FAP-positive | Primary tumor | - | - | - | - | - | ↑ | - |
STC1 [152] | - | Primary tumor | - | ↑ | - | - | - | ↑ | - |
1 Combined with high expression of α-SMA. 2 High expression levels of podoplanin in CAFs were associated with favorable clinical outcomes in CRC patients. 3 Only in patients with SMAD4-deficient tumors. CAF: cancer-associated fibroblast, CRC: colorectal cancer, ECM: extracellular matrix, α-SMA: alpha smooth muscle actin, FAP: fibroblast activation protein, COX-2: cyclooxigenase-2, HIC-5: hydrogen peroxide-inducible clone-5, FGF: fibroblast growth factor, miRNA: microRNA, CD: cluster of differentiation, RAB31: Ras-related protein RAB-31, CLEC3B: C-type lectin domain family 3 member B, SPARC: secreted protein acidic and rich in cysteine, IGF-2: insulin-like growth factor 2, CCBE1: collagen and calcium-binding epidermal growth factor domain 1, lncRNA: long non-coding RNA, TGF- β2: transforming growth factor-β2, CXCL5: C-X-C motif chemokine 5, BMP2: bone morphogenetic protein 2, IL-11: interleukin 11, STC1: stanniocalcin-1. ↑ indicates a tumor-promoting role, ↓ indicates a tumor-suppressing role, = indicates a neutral role (i.e., neither tumor-promoting nor tumor-suppressing).